Precigen (PGEN) AI Stock Analysis

• Market Cap: $1.32B
• Dividend Yield: N/A
• Average Volume (3M): 4.81M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: 59.20%
• EPS Growth: -155.65%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.06
• Shares Outstanding: 353,824,500
• 10 Day Avg. Volume: 5,838,170
• 30 Day Avg. Volume: 4,811,783
• PEG Ratio: -0.12
• Price to Book (P/B): 7.79
• Price to Sales (P/S): 76.40
• P/FCF Ratio: -3.91
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 156.55
• Enterprise Value/Gross Profit: 681.14
• Enterprise Value/Ebitda: -4.04
• 1Y Price Target: $9.00
• Price Target Upside: 140.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.39
• Revenue Forecast (FY): $12.31M

• Rating: 54 Neutral
• Price Target: $4.50 ▲(20.32% Upside)

Precigen's overall stock score is primarily influenced by its weak financial performance, which poses significant risks. However, the recent approval and deployment of Papcemias provide a positive outlook, supported by strong technical indicators. The valuation remains unattractive due to ongoing losses.

Positive Factors

FDA Approval of Papcemias

The FDA approval of Papcemias positions Precigen as a leader in treating recurrent respiratory papillomatosis, opening new revenue streams and enhancing its market position.

Revenue Growth

Strong revenue growth indicates successful commercialization efforts and expanding market presence, supporting long-term business sustainability.

Manufacturing Capacity

In-house manufacturing capacity ensures control over production quality and scalability, vital for meeting demand and maintaining competitive advantage.

Negative Factors

Weak Financial Performance

Ongoing financial struggles with negative margins and equity indicate high-risk financial health, potentially limiting growth and investment capacity.

Increased Operating Expenses

Rising operating expenses due to commercialization efforts could pressure margins and delay profitability, challenging financial stability.

Negative Cash Flow

Negative cash flow highlights difficulties in covering operational costs, which may hinder Precigen's ability to invest in growth and innovation.

Precigen Business Overview & Revenue Model

Company Description

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

How the Company Makes Money

Precigen generates revenue primarily through collaborations and partnerships with pharmaceutical companies, where it licenses its proprietary technologies and platforms for the development of therapeutic products. The company also engages in research and development agreements that provide upfront payments and potential milestone payments as projects progress. Additionally, Precigen may derive revenue from the commercialization of its own therapeutics, once they receive regulatory approval and enter the market. Key partnerships with established pharmaceutical companies and research institutions play a significant role in strengthening its revenue model, as these collaborations often include shared financial investments and resources, enhancing the company's ability to develop and bring new therapies to market.

Precigen Financial Statement Overview

Summary

Precigen's financial performance is weak, with negative net profit margins, negative equity, and poor cash flow generation. These factors indicate a high-risk financial profile with limited short-term improvement prospects.

Income Statement

Precigen's income statement reveals significant challenges. The company has been experiencing negative net profit margins, with the latest TTM data showing a net profit margin of -28.69%. Despite a slight revenue growth of 3.31% in the TTM period, the company has consistently reported negative EBIT and EBITDA margins, indicating ongoing operational inefficiencies. The gross profit margin has also been negative, reflecting cost management issues. Overall, the income statement suggests a struggling financial performance with limited profitability.

Balance Sheet

The balance sheet of Precigen highlights financial instability. The company has a negative stockholders' equity in the latest TTM period, indicating potential solvency issues. The debt-to-equity ratio is negative due to the negative equity, which is a significant red flag. Return on equity is also negative, reflecting the company's inability to generate profits from its equity base. These factors suggest a weak financial position with high risk.

Cash Flow

Precigen's cash flow statement shows some concerning trends. The company has been generating negative operating cash flow, with a TTM operating cash flow to net income ratio of -2.86, indicating poor cash generation relative to its net losses. Free cash flow growth is negative, and the free cash flow to net income ratio is slightly above 1, suggesting that while the company is managing to cover its net losses with free cash flow, the overall cash flow situation is precarious.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.31M	3.92M	6.22M	26.91M	14.27M	31.99M
Gross Profit	1.45M	-342.00K	106.00K	20.57M	-39.41M	-12.81M
EBITDA	-244.54M	-123.50M	-89.23M	-62.43M	-77.64M	-67.99M
Net Income	-246.87M	-126.23M	-95.90M	28.32M	-92.17M	-170.52M
Balance Sheet
Total Assets	171.26M	145.27M	151.04M	215.98M	359.86M	314.59M
Cash, Cash Equivalents and Short-Term Investments	121.14M	97.91M	62.85M	55.95M	108.66M	100.12M
Total Debt	98.19M	5.50M	7.10M	51.42M	190.07M	182.28M
Total Liabilities	129.40M	106.75M	32.55M	89.72M	252.51M	247.41M
Stockholders Equity	41.87M	38.51M	118.50M	126.26M	107.35M	67.17M
Cash Flow
Free Cash Flow	-75.62M	-76.76M	-68.47M	-69.97M	-63.02M	-84.55M
Operating Cash Flow	-72.61M	-68.17M	-66.93M	-65.05M	-55.77M	-77.02M
Investing Cash Flow	-106.77M	-20.71M	-3.09M	226.42M	-74.54M	27.78M
Financing Cash Flow	168.97M	110.58M	29.59M	-155.29M	121.19M	32.70M

Precigen Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.74
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Neutral. The current price of 3.74 is below the 20-day moving average (MA) of 4.09, below the 50-day MA of 3.82, and above the 200-day MA of 2.43, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.21 is Neutral, neither overbought nor oversold. The STOCH value of 7.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PGEN.

Precigen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	72 Outperform	$1.02B	25.20	19.44%	―	14.77%	-58.90%
IMNM	56 Neutral	$1.71B	―	-93.04%	―	-4.44%	63.58%
PRAX	54 Neutral	$4.71B	―	-75.20%	―	364.98%	-25.33%
PGEN	54 Neutral	$1.32B	―	-507.72%	―	59.20%	-155.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WVE	47 Neutral	$1.28B	―	-86.51%	―	103.75%	33.84%
ORIC	43 Neutral	$1.15B	―	-39.73%	―	―	4.29%

Precigen Corporate Events

Precigen’s Optimistic Earnings Call Highlights Papcemias Success

In a recent earnings call, Precigen, Inc. expressed an optimistic outlook, driven by the transformative approval and rapid deployment of their new treatment, Papcemias. The company highlighted its strong financial positioning and manufacturing capabilities, despite increased expenses, and anticipates reaching cash flow breakeven by 2026.

Precigen Reports Q3 2025 Results and PAPZIMEOS Launch

Precigen, Inc. is a biopharmaceutical company focused on developing innovative precision medicines to treat challenging diseases, particularly in the fields of immuno-oncology, autoimmune disorders, and infectious diseases.

Precigen’s Promising Phase 2 Study: PRGN-2009 and Pembrolizumab for Cervical Cancer

Precigen, Inc. is conducting a Phase 2 clinical study titled ‘A Randomized, Open-label, Two-arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy in Patients With Recurrent or Metastatic Cervical Cancer.’ The study aims to assess the efficacy and safety of combining PRGN-2009 with pembrolizumab compared to pembrolizumab alone in patients with recurrent or metastatic cervical cancer resistant to pembrolizumab. This research is significant as it explores potential new treatment avenues for a challenging cancer type.

Precigen Converts Preferred Stock to Common Shares

On September 15, 2025, Precigen, Inc. saw the conversion of 79,000 shares of its 8.00% Series A Convertible Perpetual Preferred Stock into 54,937,411 shares of common stock. This conversion was executed under the terms of the company’s Amended and Restated Articles of Incorporation, with the common stock issued on September 17, 2025. The transaction was conducted under an exemption from registration, involving an exchange with existing security holders without any commission or remuneration for solicitation.

The most recent analyst rating on (PGEN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Precigen Secures $125M Loan for PAPZIMEOS Expansion

On September 3, 2025, Precigen, Inc. announced a loan agreement with Pharmakon Advisors, LP, securing a 5-year senior secured term loan facility of up to $125 million. This non-dilutive financing, with an initial $100 million funded at closing, aims to support the commercialization of PAPZIMEOS, a novel immunotherapy, in the US and potentially expand into international markets. The agreement strengthens Precigen’s financial position, enabling it to pursue pediatric and other HPV-related indications, and is expected to drive significant growth, positioning the company as a leading biopharma innovator.

The most recent analyst rating on (PGEN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Precigen Enters Commercial Supply Agreement with Catalent

On August 13, 2025, Precigen, Inc. entered into a Commercial Supply Agreement with Catalent Maryland, Inc. This agreement mandates Catalent to provide various services including analytical, development, processing, validation, and product maintenance for Precigen’s product, PAPIZEMOS. The agreement establishes Catalent as the exclusive provider for Precigen’s commercial fill and finish manufacturing needs for PAPIZEMOS, with terms including annual price adjustments and a minimum purchase requirement. The initial term of the agreement is three years, with automatic one-year renewals unless terminated by either party. This collaboration is expected to streamline Precigen’s manufacturing processes and potentially enhance its market positioning by ensuring consistent product supply.

The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Precigen’s PAPZIMEOS Receives FDA Approval for RRP

On August 18, 2025, Precigen, Inc. announced that its product PAPZIMEOS received FDA approval as the first and only therapy for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. This approval positions PAPZIMEOS as a potential standard-of-care treatment, offering a new paradigm for managing RRP, which was previously treated mainly through surgical interventions. The approval is expected to significantly impact Precigen’s market positioning and provide a new therapeutic option for the estimated 27,000 adult RRP patients in the US.

The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.